actein and Liver-Neoplasms

actein has been researched along with Liver-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for actein and Liver-Neoplasms

ArticleYear
Actein ameliorates hepatobiliary cancer through stemness and p53 signaling regulation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 88

    Actein is isolated from the rthizomes of Cimicifuga foetida, which is a triterpene glycoside, displaying suppressive effects on breast cancer cells proliferation. However, the effects of actein treatment on liver injury, tending to cancer, have little to be known. Thus, the study is conducted to explore the role of actein in early liver cancer. Diethylnitrosamine (DEN) was used to induce liver cancer in mice followed by actein treatment at different concentrations. DEN caused steatohepatitis supported by fibrosis and inflammation, which were ameliorated for actein administration. Liver histology of mice with DEN treatment displayed hepatobiliary cysts, reversed by actein. Cell proliferation markers of Cyclin Ds and p53, as well as cancer stem cell markers of CD133 were highly increased in liver tissue samples from DEN-induced mice, and actein showed inhibitory role in these signals expression. Actein-reduced up-regulation of Hif-1α and VEGFR1 in DEN-stimulated liver tissue of mice was seen. Taken together, DEN promoted liver cancer progression, which was ameliorated by actein, supplying a potential therapeutic strategy for liver cancer in future.

    Topics: AC133 Antigen; Animals; Antineoplastic Agents, Phytogenic; Carcinogens; Cell Proliferation; Cyclin D; Cytokines; Diethylnitrosamine; Epithelial-Mesenchymal Transition; Fatty Liver; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Saponins; Signal Transduction; Triterpenes; Tumor Suppressor Protein p53

2017
Actein activates stress- and statin-associated responses and is bioavailable in Sprague-Dawley rats.
    Fundamental & clinical pharmacology, 2009, Volume: 23, Issue:3

    The purpose of this study was to assess in rats the pharmacological parameters and effects on gene expression in the liver of the triterpene glycoside actein. Actein, an active component from the herb black cohosh, has been shown to inhibit the proliferation of human breast cancer cells. To conduct our assessment, we determined the molecular effects of actein on livers from Sprague-Dawley rats treated with actein at 35.7 mg/kg for 6 and 24 h. Chemogenomic analyses indicated that actein elicited stress and statin-associated responses in the liver; actein altered expression of cholesterol and fatty acid biosynthetic genes, p53 pathway genes, CCND1 and ID3. Real-time RT-PCR validated that actein induced three time-dependent patterns of gene expression in the liver: (i) a decrease followed by a significant increase of HMGCS1, HMGCR, HSD17B7, NQO1, S100A9; (ii) a progressive increase of BZRP and CYP7A1 and (iii) a significant increase followed by a decrease of CCND1 and ID3. Consistent with actein's statin- and stress-associated responses, actein reduced free fatty acid and cholesterol content in the liver by 0.6-fold at 24 h and inhibited the growth of human HepG2 liver cancer cells. To determine the bioavailability of actein, we collected serum samples for pharmacokinetic analysis at various times up to 24 h. The serum level of actein peaked at 2.4 microg/mL at 6 h. Actein's ability to alter pathways involved in lipid disorders and carcinogenesis may make it a new agent for preventing and treating these major disorders.

    Topics: Animals; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; Cimicifuga; Fatty Acids, Nonesterified; Female; Gene Expression Regulation; Humans; Liver; Liver Neoplasms; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Saponins; Time Factors; Triterpenes

2009